CDK4/6 inhibitors for older breast cancer patients
Part of Cancer, Skin clinical trials.
This study looks at how well older breast cancer patients (70 years and older) do when treated with a type of drug called a CDK4/6 inhibitor along with hormone therapy after surgery. The goal is to use simple health checks to help doctors decide if this treatment is right for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 70 or older
- Have had surgery for breast cancer (either right away or after shrinking the tumor with treatment first)
- About to start a CDK4/6 inhibitor and hormone therapy after surgery
- Able to understand and answer questionnaires
- No trouble speaking or understanding the language used in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well CDK4/6 inhibitors work in older adults with breast cancer who are taking these drugs after surgery to help prevent the cancer from coming back. It will follow patients over time to learn more about their experiences.
This trial is testing whether adjusting the dose of a targeted therapy (CDK 4/6 inhibitor) based on a geriatric assessment can be as effective and safer for people aged 70 and older with advanced hormone receptor-positive, HER2-negative breast cancer. It aims to find the best dose to balance benefits and side effects.
This trial studies how CDK4/6 medicines fit into treatment for people with advanced hormone receptor–positive breast cancer that cannot be cured with surgery or radiation. It may help doctors understand the best way to use these medicines for disease that has returned or spread.
This trial tests a chemotherapy-free approach for women age 65 and older with a common type of breast cancer (ER-positive, HER2-negative) that has spread to lymph nodes. Instead of chemotherapy, you would receive an oral targeted therapy (CDK4/6 inhibitor) after surgery to see if it can prevent the cancer from coming back.
This study looks at how well CDK4/6 inhibitors combined with hormone therapy work in real-world settings for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to understand the best treatment path and what happens next.
This trial is for people with a common type of breast cancer that is hormone-receptor-positive and HER2-negative, and has a high risk of coming back. It looks at how well patients take a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy after surgery, to help prevent recurrence.
Hear when a new Geriatric Assessment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.